Patents by Inventor Andreas Gollner

Andreas Gollner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KRAS DEGRADING COMPOUNDS COMPRISING ANNULATED 2-AMINO-3-CYANO THIOPHENES
    Publication number: 20250145608
    Abstract: The present invention relates to compounds and derivatives of formula (I) which target KRAS and can be useful as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: November 30, 2022
    Publication date: May 8, 2025
    Inventors: Joachim BROEKER, Jason ABBOTT, Alessio CIULLI, Jianwen CUI, Emelyne DIERS, William FARNABY, Stephen W. FESIK, Andreas GOLLNER, Jake GOODWIN-TINDALL, Tim HODGES, Christiane KOFINK, Andrew LITTLE, Andreas MANTOULIDIS, Ross MCLENNAN, Johannes POPOW, Dhruba SARKAR, Martin SCHMIEDEL, Christian Alan Paul SMETHURST, Nicole TRAINOR, Alex WATERSON, Harald WEINSTABL, Siying ZHONG, David ZOLLMAN
  • ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER
    Publication number: 20250129096
    Abstract: The present invention encompasses compounds of formula (V) wherein R1a, R1b, R2a, R2b, Z, R4, R5, R14, A, p, X, U, V and W have the meanings given in the claims and specification, their use as inhibitors of KRAS, pharmaceutical compositions and preparations containing such compounds and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: November 30, 2022
    Publication date: April 24, 2025
    Inventors: Joachim BROEKER, Jason ABBOTT, Jianwen CUI, Stephen W. FESIK, Julian FUCHS, Andreas GOLLNER, Lorenz HERDEIS, Tim HODGES, Andrew LITTLE, Andreas MANTOULIDIS, Jason PHAN, Dhruba SARKAR, Christian Alan Paul SMETHURST, Qi SUN, Alex WATERSON
  • Isoindolinone substituted indoles and derivatives as RAS inhibitors
    Patent number: 12281099
    Abstract: The present invention relates to new isoindolinone or isobenzofuranone substituted indoles and derivatives of formula (I) wherein the groups R1 to R7, R10 and n have the meanings given in the claims and specification, their use as inhibitors of RAS-family proteins and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: February 25, 2020
    Date of Patent: April 22, 2025
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Mantoulidis, Andreas Gollner, Dirk Kessler, Laetitia Janine Martin, Harald Weinstabl
  • SPIROCYCLIC ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER
    Publication number: 20250019385
    Abstract: The present invention encompasses compounds of formula (I) wherein R1a, R1b, R2a, R2b, Z, R3 to R5, ring A, ring B, p, q, V and W have the meanings given in the claims and specification, their use as inhibitors of KRAS, pharmaceutical compositions and preparations containing such compounds and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: May 29, 2024
    Publication date: January 16, 2025
    Inventors: Joachim BROEKER, Jason ABBOTT, Jianwen CUI, Stephen W. FESIK, Andreas GOLLNER, Lorenz HERDEIS, Tim HODGES, Andrew LITTLE, Andreas MANTOULIDIS, Juergen RAMHARTER, Dhruba SARKAR, Kevin SOKOL, Alex WATERSON, Tobias WUNBERG
  • ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER
    Publication number: 20250002504
    Abstract: The present invention encompasses compounds of formula (I) wherein R1a, R1b, R2a, R2b, Z, R3 to R5, A, p, U, V and W have the meanings given in the claims and specification, their use as inhibitors of KRAS, pharmaceutical compositions and preparations containing such compounds and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: June 26, 2024
    Publication date: January 2, 2025
    Inventors: Joachim BROEKER, Jason ABBOTT, Jianwen CUI, Stephen W. FESIK, Julian FUCHS, Andreas GOLLNER, Lorenz HERDEIS, Tim HODGES, Andrew LITTLE, Andreas MANTOULIDIS, Jason PHAN, Juergen RAMHARTER, Dhruba SARKAR, Christian Alan Paul SMETHURST, Kevin SOKOL, Heinz STADTMUELLER, Qi SUN, Matthias TREU, Alex WATERSON, Birgit WILDING, Tobias WUNBERG
  • ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER
    Publication number: 20250002485
    Abstract: The present invention encompasses compounds of formula (I) wherein R1a, R1b, R2a, R2b, Z, R3 to R5, A, p, U, V, W, L and E have the meanings given in the claims and specification, their use as inhibitors of mutant Ras family proteins, pharmaceutical compositions and preparations containing such compounds and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: February 14, 2024
    Publication date: January 2, 2025
    Inventors: Jason ABBOTT, Joachim BROEKER, Jianwen CUI, Steve W. FESIK, Andreas GOLLNER, Tim HODGES, Jale KAROLYI-OEZGUER, Andrew LITTLE, Andreas MANTOULIDIS, Jason PHAN, Dhruba SARKAR, Christian Alan Paul SMETHURST, Qi SUN, Matthias TREU, Alex WATERSON
  • Phenyltetrazole derivatives as plasma kallikrein inhibitors
    Patent number: 12091399
    Abstract: Disclosed are phenyltetrazole derivatives of formula (I), wherein A, R1, R2, X, R?, R?, and n are as defined herein, and pharmaceutically acceptable salts thereof. Also disclosed are methods of using the phenyltetrazole derivatives for the treatment of diseases which can be influenced by inhibition of plasma kallikrein.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: September 17, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Dieter Wiedenmayer, Andreas Gollner, Iain Lingard, Holger Wagner
  • Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
    Patent number: 12060367
    Abstract: The present invention encompasses compounds of formula (I) wherein R1a, R1b, R2a, R2b, Z, R3 to R5, A, p, U, V and W have the meanings given in the claims and specification, their use as inhibitors of KRAS, pharmaceutical compositions and preparations containing such compounds and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: May 9, 2023
    Date of Patent: August 13, 2024
    Assignees: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, VANDERBILT UNIVERSITY
    Inventors: Joachim Broeker, Jason Abbott, Jianwen Cui, Stephen W. Fesik, Julian Fuchs, Andreas Gollner, Lorenz Herdeis, Tim Hodges, Andrew Little, Andreas Mantoulidis, Jason Phan, Juergen Ramharter, Dhruba Sarkar, Christian Alan Paul Smethurst, Kevin Sokol, Heinz Stadtmueller, Qi Sun, Matthias Treu, Alex Waterson, Birgit Wilding, Tobias Wunberg
  • ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER
    Publication number: 20240174690
    Abstract: The present invention encompasses compounds of formula (I) wherein R1a, R1b, R2a, R2b, Z, R3 to R5, A, p, U, V and W have the meanings given in the claims and specification, their use as inhibitors of KRAS, pharmaceutical compositions and preparations containing such compounds and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: May 9, 2023
    Publication date: May 30, 2024
    Inventors: Joachim BROEKER, Jason ABBOTT, Jianwen CUI, Stephen W. FESIK, Julian FUCHS, Andreas GOLLNER, Lorenz HERDEIS, Tim HODGES, Andrew LITTLE, Andreas MANTOULIDIS, Jason PHAN, Juergen RAMHARTER, Dhruba SARKAR, Christian Alan Paul SMETHURST, Kevin SOKOL, Heinz STADTMUELLER, Qi SUN, Matthias TREU, Alex WATERSON, Birgit WILDING, Tobias WUNBERG
  • NEW SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS
    Publication number: 20240109913
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, A, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Application
    Filed: September 8, 2023
    Publication date: April 4, 2024
    Inventors: Juergen RAMHARTER, Joachim BROEKER, Annika GILLE, Andreas GOLLNER, Manuel HENRY, Nina KERRES, Harald WEINSTABL
  • Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
    Patent number: 11945812
    Abstract: The present invention encompasses compounds of formula (I) wherein R1a, R1b, R2a, R2b, Z, R3 to R5, A, p, U, V, W, L and E have the meanings given in the claims and specification, their use as inhibitors of mutant Ras family proteins, pharmaceutical compositions and preparations containing such compounds and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: June 1, 2021
    Date of Patent: April 2, 2024
    Assignees: Boehringer Ingelheim International GmbH, Vanderbilt University
    Inventors: Jason Abbott, Joachim Broeker, Jianwen Cui, Steve W. Fesik, Andreas Gollner, Tim Hodges, Jale Karolyi-Oezguer, Andrew Little, Andreas Mantoulidis, Jason Phan, Dhruba Sarkar, Christian Alan Paul Smethurst, Qi Sun, Matthias Treu, Alex Waterson
  • ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER
    Publication number: 20230227470
    Abstract: The present invention encompasses compounds of formula (I) wherein R1a, R1b, R2a, R2b, Z, R3 to R5, A, p, U, V and W have the meanings given in the claims and specification, their use as inhibitors of KRAS, pharmaceutical compositions and preparations containing such compounds and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: November 30, 2022
    Publication date: July 20, 2023
    Inventors: Joachim BROEKER, Jason ABBOTT, Jianwen CUI, Stephen W. FESIK, Julian FUCHS, Andreas GOLLNER, Lorenz HERDEIS, Tim HODGES, Andrew LITTLE, Andreas MANTOULIDIS, Jason PHAN, Juergen RAMHARTER, Dhruba SARKAR, Christian Alan Paul SMETHURST, Kevin SOKOL, Heinz STADTMUELLER, Qi SUN, Matthias TREU, Alex WATERSON, Birgit WILDING, Tobias WUNBERG
  • ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER
    Publication number: 20230212164
    Abstract: The present invention encompasses compounds of formula (I), wherein R1a, R1b, R2a, R2b, Z, R3, R5, A, U, V, W, L and E have the meanings given in the claims and specification, their use as inhibitors of mutant Ras family proteins, pharmaceutical compositions and preparations containing such compounds and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: June 1, 2021
    Publication date: July 6, 2023
    Inventors: Jason ABBOTT, Joachim BROEKER, Jianwen CUI, Stephen W. FESIK, Andreas GOLLNER, Tim HODGES, Jale KAROLYI-OEZGUER, Andrew LITTLE, Andreas MANTOULIDIS, Jason PHAN, Dhruba SARKAR, Christian Alan Paul SMETHURST, Qi SUN, Matthias TREU, Alex WATERSON
  • NEW ISOINDOLINONE SUBSTITUTED INDOLES AND DERIVATIVES AS RAS INHIBITORS
    Publication number: 20220144810
    Abstract: The present invention relates to new isoindolinone or isobenzofuranone substituted indoles and derivatives of formula (I) wherein the groups R1 to R7, R10 and n have the meanings given in the claims and specification, their use as inhibitors of RAS-family proteins and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: February 25, 2020
    Publication date: May 12, 2022
    Inventors: Andreas MANTOULIDIS, Andreas GOLLNER, Dirk KESSLER, Laetitia Janine MARTIN, Harald WEINSTABL
  • PHENYLTETRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS
    Publication number: 20210387963
    Abstract: Disclosed are phenyltetrazole derivatives of formula (I), wherein A, R1, R2, X, R?, R?, and n are as defined herein, and pharmaceutically acceptable salts thereof. Also disclosed are methods of using the phenyltetrazole derivatives for the treatment of diseases which can be influenced by inhibition of plasma kallikrein.
    Type: Application
    Filed: October 7, 2019
    Publication date: December 16, 2021
    Inventors: Dieter WIEDENMAYER, Andreas GOLLNER, Iain LINGARD, Holger WAGNER
  • ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER
    Publication number: 20210380574
    Abstract: The present invention encompasses compounds of formula (I) wherein R1a, R1b, R2a, R2b, Z, R3 to R5, A, p, U, V, W, L and E have the meanings given in the claims and specification, their use as inhibitors of mutant Ras family proteins, pharmaceutical compositions and preparations containing such compounds and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: June 1, 2021
    Publication date: December 9, 2021
    Inventors: Jason ABBOTT, Joachim BROEKER, Jianwen CUI, Steve W. FESIK, Andreas GOLLNER, Tim HODGES, Jale KAROLYI-OEZGUER, Andrew LITTLE, Andreas MANTOULIDIS, Jason PHAN, Dhruba SARKAR, Christian Alan Paul SMETHURST, Qi SUN, Matthias TREU, Alex WATERSON
  • NEW SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS
    Publication number: 20210101912
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, A, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Application
    Filed: December 11, 2020
    Publication date: April 8, 2021
    Inventors: Juergen RAMHARTER, Joachim BROEKER, Annika GILLE, Andreas GOLLNER, Manuel HENRY, Nina KERRES, Harald WEINSTABL
  • Spiro[3H-indole-3,2?-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-p53 inhibitors
    Patent number: 10919913
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, A, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: February 16, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Juergen Ramharter, Joachim Broeker, Annika Gille, Andreas Gollner, Manuel Henry, Nina Kerres, Harald Weinstabl
  • Spiro[3H-indole-3,2?-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
    Patent number: 10882866
    Abstract: The present invention encompasses intermediates for preparing compounds of formula (I) wherein the groups R1 to R4, R7, A, D, E, F, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: January 5, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Gollner, Joachim Broeker, Nina Kerres, Christiane Kofink, Juergen Ramharter, Harald Weinstabl, Annika Gille, Stefan Goepper, Manuel Henry, Guenther Huchler
  • Spiro[3H-indole-3,2?-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
    Patent number: 10717742
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R4, R7, A, D, E, F, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: July 21, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Gollner, Joachim Broeker, Nina Kerres, Christiane Kofink, Juergen Ramharter, Harald Weinstabl, Annika Gille, Stefan Goepper, Manuel Henry, Guenther Huchler